|Mr. Albert Alexander Haeggstrom||CFO & Director||79.24k||N/A||1971|
|Prof. Edward Olof Haeggstrom||Co-Founder & CEO||N/A||N/A||1969|
|Mr. Henri von Haartman||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Peter Hanninen||General Counsel||N/A||N/A||1988|
|Dr. David Rowe||Head of Manufacturing||N/A||N/A||1967|
|Mr. Christian Jones||Chief Commercial Officer||N/A||N/A||1980|
|Mr. Antonio Da Silva||Chief of Business Operations||N/A||N/A||1974|
|Ms. Johanna Kause||Chief Quality Officer||N/A||N/A||1971|
Nanoform Finland Oyj provides nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance. It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.
Nanoform Finland Oyj’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.